MedPath

Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients

Not Applicable
Withdrawn
Conditions
Infertility
Interventions
Drug: intrauterine injection of HCG
Registration Number
NCT02870855
Lead Sponsor
Reproductive & Genetic Hospital of CITIC-Xiangya
Brief Summary

Repeated implantation failure(RIF) is a insurmountable bottleneck in assisted reproductive technology, many studies have considered that the cause of two-thirds of implant failure is the decreased endometrial receptivity. Human chorionic gonadotropin (hCG) is an early pre-plant signal molecule secreted by the embryo, it can promote endometrial proliferation, increase blood flow and promote embryonic adhesion and inhibit self-regulate apoptosis of trophoblast cells. Previous studies showed that: intrauterine injection of HCG before embryo transfer can improve clinical outcomes in IVF/Intracytoplasmic sperm injection(ICSI). But some studies found that the intrauterine injection of HCG can not significantly improve the success rate of blastocyst transfer, and the reason may be the intrauterine injection of HCG time is too late to significantly increase the implantation rate. Would ahead of intrauterine injection of HCG be more effective? Thus, the patients of repeated implantation frozen embryo cycle according to the random principle accepted two kinds of transplants ways: ①intrauterine injection of HCG before blastocyst transfer; ②blastocyst transfer. Try to understand whether intrauterine injection of HCG can significantly improve the clinical pregnancy rate of blastocyst transfer in repeated implantation failure patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • women with unexplained RIF(two to four previous embryo transfers without achieving pregnancy);
  • age<36 years;
  • frozen embryo transfer cycles
Exclusion Criteria
  • polycystic ovary syndrome
  • uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus and uterine mediastinum)
  • intrauterine adhesions
  • endometriosis
  • adenomyosis
  • hydrosalpinx
  • uterine fibroids (submucosal fibroids, non-mucosal fibroids > 4 cm and / or endometrial pressure)
  • thydroid dysfunction and hyperprolactinemia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HCG groupintrauterine injection of HCGintrauterine injection of HCG before blastocyst transfer
Primary Outcome Measures
NameTimeMethod
clinical pregnancy rateUntil 28 day after embryo transferred

clinical pregnancy rate

Secondary Outcome Measures
NameTimeMethod
ectopic pregnancy rateuntil 28 day after embryo transferred

ectopic pregnancy rate

spontaneous abortion rateuntil 28 day after embryo transferred

spontaneous abortion rate

Trial Locations

Locations (1)

Reproductive & Genetic Hospital of CITIC-XIANGYA

🇨🇳

Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath